Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies - sprookjes - yvandenbroek - TriplyDB

Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies

Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies

http://www.wikidata.org/entity/Q27486115

about

Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design The hepatitis C virus glycan shield and evasion of the humoral immune response Neutralizing antibody response to hepatitis C virus Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies In vitro selection of a neutralization-resistant hepatitis C virus escape mutant Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1 CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423 Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.Structural basis for broad neutralization of hepatitis C virus quasispecies.Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.Adaptive immunity to hepatitis C virus.Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.Molecular and contextual markers of hepatitis C virus and drug abuse.Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive Properties Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region Neutralizing antibodies and pathogenesis of hepatitis C virus infection.Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.CD81 and hepatitis C virus (HCV) infection.

P2860

Q26801759-08FDED89-2CB9-40C4-9CC9-A6AC565402B8 Q27023390-4AAC47C5-E49E-470B-A94B-5E8A478B4ABF Q27027484-1F1EA7B9-5AD2-4442-B0BD-02951A3F95EA Q27487399-A73F25EA-DF4F-4B88-8533-2D591025D079 Q27487549-E7899BD0-E414-4A33-A799-C892DF4C29D6 Q27488430-404D2A64-3E05-45C4-99B0-143129AF57DA Q27489056-098F663C-05DC-41B9-B3FC-A677D8AA8D1F Q27490450-F33F2B85-B10C-482C-9A81-EE5B62ADA7E3 Q27673453-5ED3955B-AA5E-41AD-ADAD-6685FBCEC178 Q27679280-4FE11F4C-A39F-4F83-9062-B55674EFEE51 Q28114859-80FC1E4A-B0E3-4138-8EB0-9C6BA6A23BEF Q28482261-4C0D42A5-EF65-4BF5-82DE-A46E339A0092 Q28731355-CCB48E9B-1742-48AF-B977-5EAFBE5D020F Q30374314-804EEA62-210E-454A-BF93-089BE727D9B6 Q33612608-62358D53-04B2-417A-AE86-2466B1286413 Q33628805-4A6D0C70-4B90-4566-A62C-BBFE924C2C2B Q33877342-DC75A759-A09F-4664-8527-2DB1828B1598 Q33877381-456CAE80-EC10-4366-AA3C-C6AB8A66C0B7 Q33929089-3871A545-D904-4536-999E-998604A1CEA8 Q33955998-279721AD-D0BD-45CF-9576-30D1C42A5243 Q33991988-8AD2865B-1883-4204-98DE-D750C47D11EF Q34047477-FDD785D9-1D6B-475A-8EF2-8459582E221F Q34048752-A14469DF-CDBE-44EE-A83B-2572B01E3579 Q34064882-8BF5CE3A-3BD3-44E8-B052-A780BAA55A16 Q34228030-7ECD5710-3AFE-487F-8E68-C02BE282E9AD Q34262165-F827A241-ED8E-416C-9DA8-6AD1DCC55F60 Q35259748-1AB77D9B-A17A-4589-ADB6-938E6FCE41C9 Q35274913-91B90E76-89C0-42F9-B838-306BA5FDFEE1 Q35557994-8EF0DFDA-9CB6-4EB2-B66F-E288AE7E1A85 Q35660841-074AD44E-331C-4106-894A-819F246B3560 Q35953659-19A3FAAF-D2D3-45B7-8798-C3987EC92295 Q36334312-ABF947DA-102E-4896-9281-DDE4CB2AA65D Q36395837-B18FC2A8-3E16-4B92-AB37-9D5C510E190D Q36506935-63C8F5B1-2548-48D3-B140-78B0E80D05E0 Q36693991-C0ABED4A-9C4F-45F4-B2B0-6D0639F980A4 Q36811958-D7746ABF-2349-40AD-883B-10DF31211B0C Q37336742-8E476D74-91EC-4816-B758-06AE7C36E391 Q37417999-5F6F3919-08C9-492D-9BC5-DD8067B738A6 Q37439266-BE358AE1-18A2-4F99-A6B1-321A5AB549B2 Q37611819-37A84667-6A0B-40B9-B6D1-FF86FF603104

P2860

Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies

http://www.wikidata.org/entity/Q27486115

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@ast

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@en

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@nl

type

label

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@ast

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@en

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@nl

prefLabel

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@ast

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@en

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@nl

P1433

Q27486115-BDF8C4DD-4380-49B2-8F15-92388A75B566

P1476

Q27486115-8549C6EC-536D-4B0E-8CF3-EEBD96F33309

P2093

Q27486115-06990842-897C-479E-B06C-8014AF411BB3

Q27486115-147B724D-4026-495F-B6AC-642A0F21E967

Q27486115-5709E007-E478-48CA-8973-4346F5E21E8C

Q27486115-5DA0F542-103F-48B4-8F4C-CEEBC7ACEAD6

Q27486115-68E46484-A052-43EC-82DE-A6339FD88FD0

Q27486115-7F64419B-FCB4-48DD-AE7D-8CF3ACA3260C

Q27486115-E251C4DD-EDD5-4D2E-B621-3A6171796356

Q27486115-E2800AE8-82DA-435F-82C8-71B52F6D4612

P2860

Q27486115-0AA20EB0-82DC-40CD-9EA6-B5393B761296

Q27486115-1E81AEFA-4443-4774-9F14-EB88118910A8

Q27486115-209C535E-F416-48F1-BEE6-F60EBD2BB5F1

Q27486115-222F04E1-A923-412A-BE48-8C7BAFC92B4D

Q27486115-22599F1E-2CAF-4972-A31B-FEA4F5E7E946

Q27486115-232962C3-BCB4-49A8-AFA0-24CCE46C7239

Q27486115-2944BBF9-213F-4000-B7AE-89440368C3C0

Q27486115-452D3397-8BBE-4245-A256-B6DD9911F300

Q27486115-4CDB3E1C-74C4-45F6-8C32-D30E9DA12D70

Q27486115-4FF0F0EC-809A-4387-AE16-222FE0077919

P304

Q27486115-6B9696FC-DC3F-45F2-B0E6-4A7C92BF6CBF

P31

Q27486115-6E42355F-FAD3-40B5-8707-E24754D7DE64

P356

Q27486115-36C5EFA9-0084-44C5-BA14-7A94ABB20AE6

P433

Q27486115-000EE56F-FEB5-4D3D-B692-AC85A3136D19

P478

Q27486115-3DBDD473-A9D8-4A36-A93A-B880761B7715

P50

Q27486115-83AC4A61-AE45-4F56-A63D-6319BD1F5751

Q27486115-CF9678F8-02B4-47A8-B1F2-075AA3A52B3E

P577

Q27486115-D6D59DC0-9A86-4EBE-B6C2-1F5BAAC1E433

P698

Q27486115-448B5257-3B85-409F-B20E-C04A20E9B7E5

P921

Q27486115-83AFBE30-248E-489E-8EE1-3F0B4E905722

P932

Q27486115-C34FB9D4-0171-478C-8FA4-60C6817E8ACE

P356

P1433

Journal of Virology

P1476

Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies

@en

P2093

Arvind H Patel

http://www.w3.org/2001/XMLSchema#string

Jinming Xia

http://www.w3.org/2001/XMLSchema#string

Meital Gal-Tanamy

http://www.w3.org/2001/XMLSchema#string

Sophia H Li

http://www.w3.org/2001/XMLSchema#string

Stanley M Lemon

http://www.w3.org/2001/XMLSchema#string

Steven K H Foung

http://www.w3.org/2001/XMLSchema#string

Ta-Kai Li

http://www.w3.org/2001/XMLSchema#string

Zhen-Yong Keck

http://www.w3.org/2001/XMLSchema#string

P2860

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes

Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins.

Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2

Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells.

Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.

Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells

Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

P304

6061-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02475-07

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18400849

http://www.w3.org/2001/XMLSchema#string

P921

P932

2395155

http://www.w3.org/2001/XMLSchema#string